Ionis Pharmaceuticals Inc (IONS)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ionis Pharmaceuticals Inc chart...

About the Company

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.

CEO

Brett Monia

Exchange

NASDAQ

Website

https://www.ionispharma.com/

$172M

Total Revenue

920

Employees

$6B

Market Capitalization

-14.58

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $IONS News

Ionis Pharmaceuticals Inc IONS

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)

22h ago, source:

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS – Research ...

Ionis Pharma's Phase 2 Study Of ION224 In MASH Meets Primary Goal

5d ago, source:

ION224 is designed to reduce the production of diacylglycerol acyltransferase 2 (DGAT2) in patients with MASH. Reducing the production of DGAT2 enzyme decreases the overproduction of triglycerides ...

Q4 2023 Ionis Pharmaceuticals Inc Earnings Call

26d ago, source: Yahoo Finance

Brett P. Monia; Founder, CEO & Director; Ionis Pharmaceuticals, Inc. D. Wade Walke; SVP of IR; Ionis Pharmaceuticals, Inc. Elizabeth L. Hougen; Executive VP of ...

Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows

on MSN ago, source:

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense ...

Ionis Pharma announces positive results from phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy to treat NASH/MASH

3d ago, source: Pharmabiz

Ionis Pharmaceuticals, Inc. announced positive results from a phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

24d ago, source: Yahoo Finance

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) defied analyst predictions to release its annual results, which were ahead of market expectations. The results were impressive, with revenues of US$788m ...

Ionis Pharmaceuticals

10d ago, source: Forbes

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transcript

26d ago, source: Seeking Alpha

Good morning, and welcome to the Ionis Fourth Quarter and Full Year 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...